key: cord-0308947-n17bgmsz
authors: Gicic, Amin; Li, Shiyi; Amini, Shabnam; Sim, Tin Fei; White, Christianne; Sunderland, Bruce; Czarniak, Petra
title: A cross-sectional investigation of the impact of COVID-19 on community pharmacy
date: 2022-05-18
journal: nan
DOI: 10.1016/j.rcsop.2022.100145
sha: 87860aef91708309b2dec085e4a0467a014791fc
doc_id: 308947
cord_uid: n17bgmsz

Background COVID-19 caused Australian government and state legislative/regulatory changes which impacted directly on aspects of professional community pharmacy. Objectives To examine the views and experiences of community pharmacists regarding the impact of COVID-19 on professional pharmacy services in Western Australian community pharmacies. Methods A Qualtrics questionnaire link was emailed to all 668 community pharmacies in Western Australia in March 2021. Data were collected on the impact of COVID-19 on professional pharmacy services (telehealth, digital image prescriptions, continued dispensing and emergency supply, home delivery services, medicine and medical resource substitutions), the pharmacy environment (work hours) and professional pharmacy structure (staffing and any measures implemented). Questions included 5-point Likert responses as well as yes/no or option responses. Descriptive statistics were used to summarise questionnaire responses. Chi Squared analysis was used to investigate differences between metropolitan and rural community pharmacies. Results The response rate was 97/668 (14.5%). Many pharmacies belonged to banner groups (47/95; 40.5%). Use of telehealth was reported (25/96; 26.0%), most commonly for MedsChecks. Many received digital image prescriptions (83/88; 94.3%) and continued dispensing, emergency supply requests, or both (78/84; 92.9%) daily. For home deliveries, most used pharmacy staff (56/78; 71.8%). Shortages were reported for many medicines. Panic buying/stock-piling and the media contributed to increased panic and shortages. Little change occurred in trading hours although many reported increased workloads (67/75; 89.3%). Conclusions Covid-19 has fast-tracked digitisation in Western Australian community pharmacies. This change is likely similar in other parts of Australia. This was facilitated through the expedition of regulatory changes to enable digital health. Whilst electronic prescribing has progressed, telehealth in pharmacy remained underutilised. The pandemic has contributed to pronounced medicine and medical resources shortages, which increased the workloads and pressure of community pharmacists. Pharmacists were confronted with a lot of legislative change in a short period of time. There is a need for clear and concise communication from all levels of government in future pandemics.

Involves the review of a patient's medicines by an accredited pharmacist, usually in their home, to improve the quality use of medicines and reduce the number of adverse events. An Australian initiative introduced in 2001. MedsCheck/ Diabetes MedsChecks [5] A MedsCheck is an in-pharmacy service that aims to enhance the qualityuse-of-medicines by educating patients' on their medicines, medical conditions, interactions and any issues experienced as a result of taking medicines. A Diabetes MedsCheck provides a similar service, however focusses on providing a review of a patients type 2 diabetes medicines, monitoring devices and overall management. The MedsCheck/Diabetes MedsCheck Programs are funded by the seventh Community Pharmacy Agreement, a community pharmacy contractual agreement between the Australian government and the Pharmacy Guild of Australia. The program provides for in-pharmacy reviews of consumers who are taking multiple medications and/or have newly diagnosed or poorly controlled Type 2 diabetes. Pharmaceutical Benefits Scheme (PBS) [6] An Australian Government scheme which provides a wide range of medicines for Australian citizens and permanent residents at a subsidised price. Repatriation Pharmaceutical Benefits Scheme (RPBS) [6] Provides eligible veterans of Australia's defence force with a range of medicines and wound care items at a concessional rate.

COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) virus, was announced by the World Health Organization to be a pandemic on the 11 th March 2020. [9] The severe acute respiratory infections caused by COVID-19 have had a substantial global impact. [9] [10] [11] [12] [13] [14] As of the 10 th December 2021, there were 267,184,623 confirmed cases including 5,277,327 deaths reported worldwide. [10] Its rapid spread increased the need for extensive medical resources causing an increased burden on healthcare systems globally. [9, [11] [12] [13] Healthcare workers were faced with high infection risks, increased workloads, and psychological stress. [14, 15] Despite Australia's comparatively lower cumulative death toll compared to most of the world, the burden to its healthcare system was substantially increased, which required changes implemented as COVID-19 emergency response plans. [16] The Australian government ensured the continued supply of medicines to patients by continuing Pharmaceutical Benefits Scheme (PBS) subsidisation [see Glossary for definitions of all services]. In addition, services introduced included home delivery services (up to once a month) for PBS or Repatriation PBS medicines, digital image prescriptions, telephone medication reviews, and telehealth for MedsCheck and Diabetes MedsCheck. [16] The Pharmaceutical Society of Australia (PSA) provided information based on federal government updates on the management of COVID-19. [16] The Pharmacy Guild of Australia (Guild) developed a guideline to aid in the management of 'cold-and-flu' symptoms by advertising social distancing, hygiene maintenance, and the triaging of patients. [16] The Society of Hospital Pharmacists of Australia enabled pharmacists to undergo free hospital training and upskilling packages, and the National Pharmaceutical Services Association provided updates concerning the availability of medicine stock. [16] With its first case recognised on the 25th January 2020, COVID-19's impact in Australia was marked from March 2020 onwards, where an AUD$2.4 billion dollar health package was established to provide essential care in terms of: personal protective equipment, aged care, and primary care for non-hospital treatments. [17] [18] [19] Specific to community pharmacies, legislative and regulatory changes were introduced by both the Australian and state governments, which changed aspects of professional pharmacy, especially professional pharmacy services, the pharmacy J o u r n a l P r e -p r o o f Journal Pre-proof environment, and structure ( Figure 1 ). [1, [20] [21] [22] These included adjustments to: patient-healthcare worker interactions and sharing health-information through electronic media (telehealth); prescription options moving from paper-based to include digital (digital image prescriptions), dispensing without current prescriptions (continued dispensing and emergency supply), increased medicine deliveries (home delivery services), and medicines substitution and personal protective equipment (PPE) due to shortages. [1, 22, 23] In contrast to other Australian states, Western Australia (WA) has been less affected by 18, 24] This was mainly due to the extended closure of the WA border to other states/territories of Australia, which was not possible for other states owing to large population areas close to their borders. This resulted in less exposure of the WA populations to especially the delta strain of COVID-19 compared to other states and internationally. WA is the largest state in Australia, with widespread pockets of rural and regional communities distributed across the state. In many of these WA communities, access to other healthcare is limited.

We have previously reported on services provided in community pharmacies in WA. [25] However, the impact of COVID-19 on WA community pharmacies has not thus far been reported. [18, 24] It is unknown whether changes to professional-workplace services, environment and structure had desirable outcomes, and what impact these changes had on normal practice. Lastly, whether COVID-19 related legislative and policy changes were difficult to enforce, whether differences existed between metropolitan and rural pharmacies, or whether they lead to fragmentation in WA community pharmacy practice is unknown. [21, 26, 27] 

To examine the views and experiences of community pharmacists regarding the impact of COVID-19 on professional pharmacy services in Western Australian community pharmacies. 

A questionnaire was developed to explore the implications of COVID-19's impact on WA community pharmacies. It consisted of 5 sections with 42 questions: Section 1demographic data, Section 2professional pharmacy services (telehealth, digital image prescriptions, continued dispensing and emergency supply, home delivery services, medicine and medical resource substitutions), Section 3professional pharmacy environment, Section 4professional pharmacy structure and Section 5 - to that question was used as the baseline.

Of States that established a preference for electronic-prescriptions over paper-based prescriptions, increased authorisation and reliance on new services, and increasing the provision of essential services by increasing the supply of medicines in order to limit face-to-face contacts and decrease the risk of transmission. [28] [29] [30] [31] [32] It was notable that most respondents used their own pharmacy staff to conduct home delivery services and rated themselves highest (median score 9/10) in terms of satisfaction of completing said delivery services. Interestingly, a study in China reported increased usage of telepharmacy during COVID-19 as opposed to face-to-face consults, which was at variance with these findings which indicated a very limited uptake of telehealth. [31] This could be due to different healthcare systems but it could also be due to the fact that community pharmacies in WA were deemed as essential and remained open during the pandemic, so the need for increased telehealth appeared to be less than for other health professional services such as doctors who were usually only available via telehealth.

COVID-19 increased pharmacist workloads, and medicine and medical resource shortages and therefore medicine substitutions, especially during the period from the 1st March 2020 to the 31 st May 2020 rather than from the 1st June 2020 to the 31st December 2020. Metropolitan community pharmacies had significantly greater levels of medicine shortages than rural community pharmacies.

The shortage of medicines and medical devices was expected and may be partially explained by panic J o u r n a l P r e -p r o o f buying/stock-piling behaviours, and the influence of mainstream/social-media platforms. Supporting the current findings, a cross-sectional study in Egypt also reported an increased demand for medicines leading to medicine (antivirals) and medical devices, including PPE shortages. [32] The requirement of having to check that original paper-based prescriptions were subsequently provided to the pharmacy, and that changes to professional pharmacy practice in terms of the utilisation of new services also contributed to increased workloads. Regarding actions taken in the pharmacy, most metropolitan community pharmacies reported availability of customer shields, and selected 'yes' to wearing masks and asking for a consumers travel history, however rural community pharmacies had mixed responses.

COVID-19 resulted in regulatory and legislative changes which led to digital/online methods of practice. This impacted on professional pharmacy services, environment, and structure and caused some level of fragmentation in work pattern but little or no change in staffing or rostering schedules.

In addition to the remuneration for services by the Australian Government, a significant number of community pharmacies did not receive payment for most home delivery services. Medicine and medical resource shortages were a major factor increasing workload and almost half had their workload increased by more than 40 minutes per day.

In response to 'coping with a similar pandemic/emergency situation in the future', a majority of respondents were confident of their abilities. However, respondents emphasised that there were increases in workload; there was a general 'silence' from the government surrounding changes; there was conflicting information between federal and state Ministers. Additionally, most argued that better exemption and compensation systems were needed, that pharmacy owners and other professions were more supported than pharmacy staff who were overworked and received no benefits therefore needing to overwork for little remuneration. These findings may contribute to increasing awareness within the pharmacy profession by providing feedback to government authority-bodies about regulatory changes and their impact on community pharmacy..

There were several limitations associated with this study. Although COVID-19 expedited regulatory changes and increased the use of several pharmacy services, some digital services were in the pilot phase in some pharmacies prior to COVID-19. However, COVID-19 caused them to be immediately implemented in all pharmacies. Further, other services such as emergency supply, digital image prescriptions and continued dispensing had temporary legislation implemented specifically due to COVID-19 of which some legislation has subsequently been retained. [33] A low response rate was this investigation's greatest limitation; this was likely due to completing the questionnaire on the dispensing computer, which was also used for other purposes; the length of questionnaire, its large scope, competing demands of pharmacists leading to time constraints. This limits the generalisability of its findings within the broader Australian context. In addition, the respondents may not represent the collective thoughts of all pharmacists. Another limitation is the lapse in time before the data were collected, considering that COVID-19 is a rapidly changing space (i.e., the situation is different now to when the pandemic first started). However, we ensured that a requirement of respondents was that they had worked during the COVID-19 period. The pandemic has been a very memorable event for pharmacists, especially as it is an ongoing issue. Further, the lessons learned are still relevant as the profession needs to be agile to respond to emergencies like this when future pandemics, bushfires or other emergencies arise.

The current investigation has established that community pharmacies have adopted additional mechanisms to reduce paper-based methods of ensuring continued patient access to medicines and care in a timely manner, with increased use of digital/online-based methods. This is particularly relevant especially in cases when a person needed to be in isolation and had accessed telehealth and digital image prescriptions. This holds true for all professional pharmacy services excluding telehealth. Additionally, COVID-19 contributed to pronounced medicine and medical resource shortages, which increased the workloads of community pharmacists. Pharmacists accepted and adapted to new rules/regulatory changes, making policy changes overall not difficult to enforce.

During the main COVID-19 crisis a general lack of consistent guidance from government regulatory J o u r n a l P r e -p r o o f bodies occurred. However, community pharmacies typically showed high levels of resilience in responding to pandemic/emergency situations. J o u r n a l P r e -p r o o f The number of deliveries that were unremunerated (n = 76) 41 53. 9 Table 3 . Professional pharmacy environment, professional pharmacy structure, and associated parameters (* due to personal health issues, some staff were asked not to work and replaced by new staff)

No change, Health issues * 4

No change, Health issues * , Resigned 1

No change, Resigned 7 10.4 

Summary of COVID-19 regulatory changes Australia: Pharmaceutical Society of Australia Ltd

Electronic Prescriptions Australia: Pharmaceutical Society of Australia Ltd

Home Delivery

Australian Government Department of Health. Pharmacy programs administrator: home medicines review

Pharmacy programs administrator: program rules MedsCheck and Diabetes MedsCheck

Australian Government Department of Health. The Pharmaceutical Benefits Scheme 2021

Pharmacy programs administrator: Residential Medication Management Review and quality use of medicines

COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics

COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

COVID-19 and Italy: what next?

The COVID-19 pandemic: major risks to healthcare and other workers on the front line

On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis

Pharmacy practice in emergency response during the COVID-19 pandemic: Lessons from Australia. Res Soc Adm Pharm. 2021. 17. Ministers: Department of Health. First confirmed case of novel coronavirus in Australia

Australian Government Department of Health. Coronavvirus (COVID-19) case numbers and statistics 2021

Prime Minister of Australia. $2.4 billion health plan to fight COVID-19

The legal extension of the role of pharmacists in light of the COVID-19 global pandemic

Australia's national COVID-19 primary care response

Strategies to promote access to medications during the COVID-19 pandemic

Providing health care face to face during COVID-19 2020

Australian government Department of Health. Coronavirus COVID-19 in Western Australia 2021

A cross-sectional survey of enhanced and extended professional services in community pharmacies: A pharmacy perspective

Community pharmacy response to infection control during COVID-19. A cross-sectional survey

A scoping review of the use and impact of telehealth medication reviews

Impact of the COVID-19 epidemic on the provision of pharmaceutical care in community pharmacies

Is the paradigm of community pharmacy practice expected to shift due to COVID-19?

Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond

Providing pharmacy services during the coronavirus pandemic

Pandemic preparedness of community pharmacies for COVID

Pharmaceutical Society of Australia. Digital health guidelines for pharmacists Deakin West ACT: Pharmaceutical Society of Australia Ltd

The authors would like to acknowledge the Pharmacy Registration Board of Western Australia, who kindly distributed the link to the questionnaire to WA community pharmacies, and they would like toThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Health issues * 1

Health issues * , Employed 4

Health issues * , Resigned